Does Leqvio (Inclisiran) Affect Lp(a)? Clinical Evidence and Monitoring
Inclisiran (Leqvio) modestly reduces Lp(a) by 15 to 20% through PCSK9 silencing. Review of ORION trial data, mechanism, monitoring timing, and clinical significance for cardiovascular risk.
Read clinical review